Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business News, In Brief

Executive Summary

Quintiles files IPO; Forest sees LAMA/LABA combo product, slated for a 2014 NDA, as filling out a suite of COPD drugs to cover the full range of disease severity. Plus news from a host of biopharma quarterly earnings calls.

You may also be interested in...



New COPD Candidates Could Get Hung Up On Safety Concerns

FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.

Newly Appointed Head of Regenerative Medicine At Shire Plans Rapid Growth For The Division

Jeff Jonas takes over Shire’s newly formed Regenerative Medicine business with plans for rapid growth, replacing Advanced BioHealing’s Kevin Rakin in the role.

GSK/Theravance Breathing Easy: Once-Daily COPD Combo Expected To Meet Regulatory Standards

With largely positive results from four of seven Phase III studies, GlaxoSmithKline and Theravance say they are on track for filing their LABA/LAMA combination UMEC/VI at the end of 2012. But some analysts are wary about regulatory prospects for any LABA-containing drugs and say concerns about dosing could trip up U.S. filing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel